Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Zai Lab (Shanghai) Co., Ltd.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Aged 18 years or older female.
High-grade serous or dominantly high-grade serous ovarian cancer
The subject shall have received two lines of platinum-containing chemotherapy, complete response \[CR\] or partial response \[PR\] after first-line platinum-containing chemotherapy, and after received at least 4 cycles of platinum-containing (must be carboplatin or cisplatin or nedaplatin) in second-line platinum-containing chemotherapy.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
You may not be if
Patients who have undergone ascites drainage with the last two cycles of the last chemotherapy regimen prior to enrollment.
Symptomatic brain metastases or leptomeningeal metastases that have not been controlled.
Patients who have been diagnosed previously or currently with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
Clareo Health | Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient
